Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we read about a big acquisition fueled by obesity, doctors shifting their views on biopharma marketing, see a rare disease drug win approval after a long stretch of uncertainty, and more.
Pfizer to acquire Metsera, developer of obesity drugs
Pfizer is paying $47.50 a share in cash for Metsera, a 43% premium on the startup’s closing price on Friday that gives the deal an enterprise value of $4.9 billion. The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulatory milestones for Metsera’s medicines.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
